Avenue Therapeutics’ transition in 2025 involved significant portfolio pruning with the termination of the AJ201 license and sale of BAER-101, leading to improved operating income primarily due to reduced R&D. The company’s strategic pivot centers on intravenous tramadol as its lead clinical candidate for acute post-operative pain. However, delisting from Nasdaq has constrained traditional financing avenues, forcing dependence on OTC markets and equity sales to sustain operations. Future growth hinges on clinical progress with tramadol and the recently licensed ATX-04 asset, while liquidity risks and regulatory uncertainties remain material hurdles.